Results 261 to 270 of about 897,077 (404)
In this study, a computational pipeline is developed to systematically evaluate the conformational stability, disulfide bond reduction state, and aggregation and degradation tendencies of an anticancer VHH‐Fc fusion antibody. Based on the mechanistic insights, antibody variants with enhanced stability and increased yield are successfully designed. This
Yuan Fang+10 more
wiley +1 more source
SHINE: Deterministic Many-to-Many Clustering of Molecular Pathways. [PDF]
Chen L+4 more
europepmc +1 more source
This study have loaded chiral gold nanoclusters onto the inner and outer surfaces of ZIF and uncovers the biodistribution, metabolic variances, and therapeutic mechanism of chiral nanoparticles, providing deep insights into the nanobiological effects of chiral anti‐inflammatory nanomedicines in PD therapy for future clinical transformation.
Junyang Chen+7 more
wiley +1 more source
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu+10 more
wiley +1 more source
Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease
W. Kim+3 more
semanticscholar +1 more source
Promoter engineering for enhanced 3-hydroxypropionic acid production in <i>Pichia pastoris</i>. [PDF]
Chen S+8 more
europepmc +1 more source
Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury
Dipyridamole acts as a clinically used compound to suppress ferroptosis. Dipyridamole down‐regulates the expression of RNF126, which is an E3 ligase to ubiquitinate SLC7A11 for proteasome degradation. The deficiency of SLC7A11 largely abolishes the protective role of dipyridamole both in vitro and in vivo.
Xiao Zhuang+22 more
wiley +1 more source